Navigation Links
Winnick Family Clinical Research Center Celebrates 6th Anniversary
Date:3/3/2008

Center's Innovative Research Program Continues to Draw Accolades from

Cedars-Sinai Medical Community

LOS ANGELES, March 3 /PRNewswire/ -- The Winnick Family Clinical Research Center celebrated its sixth anniversary this month and announced that it has 60 active research protocols at the Center in 2008, representing 210 clinical researchers at Cedars-Sinai Medical Center. These researchers are active in areas ranging from women's health and the genetics of common diseases to mitochondrial genetics, insulin resistance and AIDS. The Winnick Family Foundation, founded by business visionary Gary Winnick, funds the Winnick Family Clinical Research Center at Cedars-Sinai Medical Center and the critical research that takes place at its facility.

"We continue to be hugely encouraged and inspired in our research by the generous support from the Winnick Family Foundation," said Dr. Shlomo Melmed, senior vice president academic affairs of Cedars-Sinai Medical Center. "With the breakthroughs in genetic research now coming faster and gaining in practical medical relevance all the time, the generous donations made to our genetic research programs by Gary Winnick through his foundation to the Winnick Family Clinical Research Center are enabling us to explore whole new treatment protocols with the potential to improve quality of life and life expectancy for thousands of patients suffering from a wide spectrum of illnesses. We look forward to continuing our dynamic relationship with Gary and the Winnick Family Foundation for many years to come."

"It's been an honor for us to make a contribution toward the immensely important research work being carried out at Cedars-Sinai," said Gary Winnick, founder and president of the Winnick Family Foundation. "Since the beginning of our relationship with the Center, it was crucial that the innovative, exciting work being carried out with the support of the Winnick Family Foundation give special emphasis to patient-oriented research. We are confident that this is the cutting-edge of clinical research. Our hopes have been amply rewarded by the Center's groundbreaking research into some of the afflictions that are among the greatest scourges of our society. It's wonderful to see young, gifted scientists taking up the torch of pioneering research in the Human Genome era, and we can't wait to see what the 2008 Winnick Clinical Scholars and larger body of researchers at the Winnick Family Clinical Research Center will be working on over the coming year."

The Winnick Family Clinical Research Center is a fully staffed center for clinical research active in all major clinical departments, utilizing administration, nursing, and nutritional support, along with core laboratory services in sample processing, tissue culture, genome screening and bioinformatics.


'/>"/>
SOURCE Winnick Family Clinical Research Center
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. IsoTis Receives FDA Clearance for Accell Family of Products
2. Cardica and Cook Sign Agreement to Expand Cook Vascular Closure Device Product Family
3. Melanoma Research Foundation and Seattle Cancer Care Alliance Host Educational Symposium and Reception for Melanoma Patients, Family Members and Healthcare Providers
4. Chindexs United Family Hospitals and Clinics and NBC Enter into Healthcare Services Agreement
5. Dr. Charles A. Sims of California Cryobanks Family Cord Blood Services Named to National Stem Cell Advisory Council
6. Vaccines are Likely to Cause Insulin Dependent Diabetes in Over 2% of Children With a Strong Family History of Insulin Dependent Diabetes, New Data Indicates
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
10. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
11. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today in ... patient who developed lymphedema after being treated for breast cancer benefitted from an injection ... for dealing with this debilitating, frequent side effect of cancer treatment. , ...
Breaking Biology Technology:
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
Breaking Biology News(10 mins):